Neuroprotective Effect of Cannabidiol Against Hydrogen Peroxide in Hippocampal Neuron Culture Jungnam Kim, Ji Yu Choi, Jeongyeon Seo, and Insung S. Choi Cannabis and Cannabinoid Research, 2021, Volume 6, Number 1, 40-48. Doi : 10.1089/can.2019.0102 Abstract Introduction : Reports on the neurotoxic and neuroprotective effects of cannabidiol (CBD) have not been in complete accord, showing different and somewhat contradictory results depending upon the brain cell types and experimental conditions employed. This work systematically examines the neuroprotective capability of CBD against oxidative stress (i.e., hydrogen peroxide [H2O2]) as well as its toxicity profile in the in vitro culture platform of primary hippocampal neurons. Materials and Methods : [...]
Lire la suiteReducing Effect of Cannabidiol on Alcohol Self-Administration in Sardinian Alcohol-Preferring Rats Paola Maccioni, Jessica Bratzu, Mauro A.M. Carai, Giancarlo Colombo, and Gian Luigi Gessa Cannabis and Cannabinoid Research, 2021, Doi : 10.1089/can.2020.0132 Abstract Introduction : Cannabidiol (CBD) is a major cannabinoid extracted from Cannabis sativa with no abuse potential. Data from recent rodent studies suggest that amelioration of alcohol-motivated behaviors may be one of the numerous pharmacological effects of CBD. This study was designed to contribute to this research, assessing the effect of CBD on operant oral alcohol self-administration in selectively bred Sardinian alcohol preferring (sP) rats, a validated animal model of excessive alcohol consumption. [...]
Lire la suiteCannabinoids, Phenolics, Terpenes and Alkaloids of Cannabis Mohamed M. Radwan, Suman Chandra, Shahbaz Gul and Mahmoud A. ElSohly Molecules, 2021, 26, 2774. Doi : 10.3390/molecules26092774 Abstract : Cannabis sativa is one of the oldest medicinal plants in the world. It was introduced into western medicine during the early 19th century. It contains a complex mixture of secondary metabolites, including cannabinoids and non-cannabinoid-type constituents. More than 500 compounds have been reported from C. sativa, of which 125 cannabinoids have been isolated and/or identified as cannabinoids. Cannabinoids are C21 terpeno phenolic compounds specific to Cannabis. The non-cannabinoid constituents include: non-cannabinoid phenols, flavonoids, terpenes, alkaloids and others. This review discusses [...]
Lire la suiteProtective Effects of Cannabidivarin and Cannabigerol on Cells of the Blood–Brain Barrier Under Ischemic Conditions Nicole L. Stone, Timothy J. England, and Saoirse E. O’Sullivan Cannabis and Cannabinoid Research, 2021, Doi : 10.1089/can.2020.0159 Abstract Background and Objectives : Preclinical studies have shown cannabidiol is protective in models of ischemic stroke. Based on results from our recent systematic review, we investigated the effects of two promising neuroprotective phytocannabinoids, cannabigerol (CBG) and cannabidivarin (CBDV), on cells of the blood–brain barrier (BBB), namely human brain microvascular endothelial cells (HBMECs), pericytes, and astrocytes. Experimental Approach : Cultures were subjected to oxygen-glucose deprivation (OGD) protocol to model ischemic stroke and cell [...]
Lire la suiteNew Insights on Hemp Oil Enriched in Cannabidiol: Decarboxylation, Antioxidant Properties and In Vitro Anticancer Effect Anca Roxana Petrovici, Natalia Simionescu, Andreea Isabela Sandu, Vasile Paraschiv, Mihaela Silion and Mariana Pinteala Antioxidants, 2021, 10, 738. doi : 10.3390/antiox10050738 Abstract : This study aimed to obtain and characterize extracted hemp oil enriched in cannabidiol (CBD) by decarboxylation of cannabidiolic acid (CBDA) and to give new insights into its antioxidant and anticancer effects. Optimization of CBDA decarboxylation in hemp oil was performed, and CBD and CBDA contents and purities were determined by flash chromatography, 1H- and 13C-NMR. The antioxidant properties of CBD-enriched oil were investigated by Fe2+ [...]
Lire la suiteCannabis-related diagnosis in pregnancy and adverse maternal and infant outcomes Gretchen Bandoli, Laura Jelliffe-Pawlowski, Benjamin Schumacher, Rebecca J. Baer, Jennifer N. Felder, Jonathan D. Fuchs, Scott P. Oltman, Martina A. Steurer, Carla Marienfeld Drug and Alcohol Dependence, 2021, 225, 108757. doi : 10.1016/j.drugalcdep.2021.108757 Abstract Background: Cannabis use and cannabis use disorders are increasing in prevalence, including among pregnant women. The objective was to evaluate the association of a cannabis-related diagnosis (CRD) in pregnancy and adverse maternal and infant outcomes. Methods: We queried an administrative birth cohort of singleton deliveries in California between 2011-2017 linked to maternal and infant hospital discharge records. We [...]
Lire la suiteCannabis and cannabinoid use in autism spectrum disorder : a systematic review Estácio Amaro da Silva Junior, Wandersonia Moreira Brito Medeiros, Nelson Torro, João Marçal Medeiros de Sousa, Igor Bronzeado Cahino Moura de Almeida, Filipe Barbosa da Costa, Katiúscia Moreira Pontes, Eliane Lima Guerra Nunes, Marine Diniz da Rosa, Katy Lísias Gondim Dias de Albuquerque Trends in Psychiatry and Psychotherapy, 2021, 1-10. Doi : 10.47626/2237-6089-2020-0149 Abstract Introduction : Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by persistent deficits in social communication and social interaction, associated with the presence of restricted and repetitive patterns of behavior, interests, or activities. Cannabis has been used to alleviate [...]
Lire la suiteA single dose of psilocybin increases synaptic density and decreases 5-HT2A receptor density in the pig brain Nakul Ravi Raval, Annette Johansen, Lene Lundgaard Donovan, Nidia Fernandez Ros, Brice Ozenne, Hanne Demant Hansen, Gitte Moos Knudsen Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 30 November 2020 doi : 10.20944/preprints202011.0742.v1 Abstract : A single dose of psilocybin, a psychedelic and serotonin 2A receptor (5 HT2AR) agonist, may be associated with antidepressant effects. The mechanism behind its antidepressive action is unknown but could be linked to increased synaptogenesis and down-regulation of cerebral 5-HT2AR. Here, we investigate if a single psychedelic dose of psilocybin changes synaptic vesicle protein 2A [...]
Lire la suiteAssociation of Cannabis Use During Adolescence With Neurodevelopment Matthew D. Albaugh, PhD; Jonatan Ottino-Gonzalez, PhD; Amanda Sidwell, BS; Claude Lepage, PhD; Anthony Juliano, PsyD; Max M. Owens, PhD; Bader Chaarani, PhD; Philip Spechler, PhD; Nicholas Fontaine, BS; Pierre Rioux, MSc; Lindsay Lewis, PhD; Seun Jeon, PhD; Alan Evans, PhD; Deepak D’Souza, MD; Rajiv Radhakrishnan, MD; Tobias Banaschewski, MD, PhD; Arun L.W. Bokde, PhD; Erin Burke Quinlan, PhD; Patricia Conrod, PhD; Sylvane Desrivières, PhD; Herta Flor, PhD; Antoine Grigis, PhD; Penny Gowland, PhD; Andreas Heinz, MD, PhD; Bernd Ittermann, PhD; Jean-Luc Martinot,MD, PhD; Marie-Laure Paillère Martinot,MD, PhD; Frauke Nees, PhD; Dimitri Papadopoulos [...]
Lire la suiteLow-Dose Nitrous Oxide Shows Benefit for Resistant Depression Batya Swift Yasgur, MA, LSW Medscape.com, 2021 June 17, 2021 A 1-hour treatment with a low concentration of nitrous oxide, commonly known as "laughing gas," appears to relieve symptoms of treatment-resistant major depression (TRMD), with effects lasting as long as several weeks, new research suggests. In a trial with a crossover design, investigators randomly assigned 28 patients with severe TRMD to receive a single 1-hour inhalation of placebo or nitrous oxide once a month over a 3-month period. Participants received an inhalation of placebo; a 25% concentration of nitrous oxide; and a 50% concentration of nitrous oxide. Sessions were [...]
Lire la suite